[First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease].

PubWeight™: 0.75‹?›

🔗 View Article (PMID 19283903)

Published in Vestn Ross Akad Med Nauk on January 01, 2009

Authors

V I Vasil'ev, O A Logvinenko, N V Kokosadze, I V Gaĭduk, E Iu Varlamova, A M Kovrigina, V R Gorodetskiĭ, E L Nasonov

Articles by these authors

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96

[C-reactive protein--marker of inflammation in atherosclerosis (new data)]. Kardiologiia (2002) 0.88

[Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova (1999) 0.87

[Neopterin: new immunological marker of autoimmune rheumatic disease]. Klin Med (Mosk) (2000) 0.83

Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis (2006) 0.83

[Synchronous and metachronous myeloid and lymphoid tumors]. Ter Arkh (2014) 0.82

[Cardiolipin antibodies in acute rheumatic fever]. Klin Med (Mosk) (1992) 0.82

[Anti-phosphatidylethanolamine antibodies in patients with Sneddon's syndrome]. Klin Med (Mosk) (2005) 0.82

[Changes in the indicators of bone marrow and blood based on the complex cytological examination of 28 children from the Bryansk region 1 year after the accident at the Chernobyl atomic power plant]. Gematol Transfuziol (1991) 0.82

[Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment]. Klin Med (Mosk) (2014) 0.82

[POEMS-syndrome: a literature review and case reports]. Zh Nevrol Psikhiatr Im S S Korsakova (2014) 0.81

[The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results]. Ter Arkh (2012) 0.81

[Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis]. Klin Med (Mosk) (1998) 0.80

[Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris]. Kardiologiia (1992) 0.80

[Prevalence of mental disorders in SLE patients: correlations with the disease activity and comorbid chronic conditions]. Ter Arkh (2009) 0.80

C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations. Artif Organs (1992) 0.80

[DNA-hydrolyzing antibodies in lymphoproliferative disorders]. Biull Eksp Biol Med (1996) 0.80

[Effect of small-dose glucocorticoids on the course of early rheumatic arthritis]. Klin Med (Mosk) (2004) 0.79

[Tuberculosis of the lungs complicated by opisthorchiasis under conditions of the extreme north]. Probl Tuberk (1989) 0.79

[Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren's disease]. Ter Arkh (2004) 0.79

[Serum neopterin in hepatitis B]. Klin Med (Mosk) (1992) 0.78

[New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Ter Arkh (2010) 0.78

[Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis]. Ter Arkh (1999) 0.78

[The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis]. Klin Med (Mosk) (2014) 0.77

[The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis]. Ter Arkh (2013) 0.77

[Role of splenectomy in the treatment of myelofibrosis]. Ter Arkh (2013) 0.77

[Stomach MALT-lymphoma with marked plasmocytic differentiation: a variant of Mott's cell tumor]. Arkh Patol (2004) 0.77

[Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases]. Vestn Oftalmol (2002) 0.77

[The von Willebrand factor antigen in patients with rheumatoid arthritis: a method for its determination and the clinical significance]. Ter Arkh (1993) 0.77

[Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis]. Ter Arkh (2009) 0.77

[Serum nitrates in patients with systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2004) 0.77

[Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial]. Ter Arkh (2005) 0.77

[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Ter Arkh (2013) 0.77

[Cardiovascular diseases in rheumatoid arthritis]. Ter Arkh (2007) 0.77

[Prospects for the assessment of cardiac rhythm variability in patients with rheumatoid arthritis and systemic lupus erythematosus]. Vestn Ross Akad Med Nauk (2010) 0.77

[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus]. Kardiologiia (2002) 0.77

[The hypophyseal-testicular system in cryptorchism patients following surgical treatment]. Probl Endokrinol (Mosk) (1990) 0.76

[Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2006) 0.76

[Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Ter Arkh (2008) 0.76

[Autoantibodies Against beta(1)-Adrenoreceptors in Patients With Cardiac Rhythm Disorders. Prevalence and Possible Role in Development of Arrhythmia]. Kardiologiia (2004) 0.76

[Soluble adhesion molecules (P-selectin, ICAM-1 and ICAM-3) in rheumatoid arthritis]. Ter Arkh (1999) 0.76

Anticardiolipin antibodies in Sneddon's syndrome. Neurology (1990) 0.76

[Cognitive impairment and anxiety-depressive disorders in patients with rheumatoid arthritis]. Zh Nevrol Psikhiatr Im S S Korsakova (2012) 0.76

[Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) (1998) 0.76

[The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II]. Ter Arkh (1989) 0.76

[Soluble receptors of TNF-alpha in rheumatoid arthritis]. Klin Med (Mosk) (2001) 0.76

Sneddon's syndrome: cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol (1991) 0.76

[The clinical significance of neopterin in human diseases]. Ter Arkh (1993) 0.76

[Sneddon's syndrome and the primary antiphospholipid syndrome]. Ter Arkh (1993) 0.76

[Soluble receptors of TNF-alpha with molecular mass 55 kDa in rheumatoid arthritis: clinical role]. Klin Med (Mosk) (2003) 0.76

[Differential diagnosis of Wegener's granulomatosis and extranodal NK/T-cell lymphoma, nasal type]. Ter Arkh (2012) 0.76

[Pharmacotherapy of rheumatoid arthritis: the 21st century]. Klin Med (Mosk) (2005) 0.75

[The renin-angiotensin-aldosterone system and arterial hypertension in patients with rheumatoid arthritis]. Klin Med (Mosk) (1991) 0.75

[Combined medication ARTRA in the treatment of osteoarthrosis]. Ter Arkh (2005) 0.75

[Anti-cardiolipin antibodies: a method of their detection and clinical significance]. Klin Med (Mosk) (1987) 0.75

[Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data]. Ter Arkh (2012) 0.75

[Immune mechanisms of the development of chronic diseases of the liver (review of the literature)]. Ter Arkh (1973) 0.75

[Scintigraphy in primary hypogonadism with testis transplantation]. Med Radiol (Mosk) (1979) 0.75

[Anomalous sedimentation schlieren diagrams of the blood in patients with rheumatic diseases as an indicator of the presence of reversibly dissociating immune complexes]. Biull Eksp Biol Med (1987) 0.75

[Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma]. Ter Arkh (2008) 0.75

[Hepatitis B surface antigen in chronic active hepatitis and primary biliary cirrhosis]. Sov Med (1978) 0.75

[Immunodepressants in chronic liver diseases (a review of the literature and the authors' own data)]. Ter Arkh (1976) 0.75

[Antibodies to smooth muscle in chronic liver diseases]. Ter Arkh (1975) 0.75

[Renin activity and functional status of the adrenal cortex in surgical intervention during ketamine anesthesia]. Vestn Khir Im I I Grek (1979) 0.75

[The first experience of using rituximab in Mikulicz disease]. Ter Arkh (2010) 0.75

[Differential diagnosis of rheumatic diseases and blood cancers involving the nasal cavity and accessory sinuses]. Ter Arkh (2014) 0.75

[Australian antigen and its role in the pathology of the liver]. Ter Arkh (1971) 0.75

[Comparative evaluation of the treatment of Sjögren's syndrome with anti-rheumatic preparations]. Ter Arkh (1988) 0.75

[Renal insufficiency due to interstitial nephritis in sarcoidosis]. Ter Arkh (2009) 0.75

[Diagnosis of liver disorder in amyloidosis]. Ter Arkh (1975) 0.75

[Hyperuricemia, gout and gout-induced nephropathy]. Ter Arkh (1980) 0.75

[A positive effect of combined therapy (plasmapheresis in combination with pulse therapy) on the course of cryoglobulinemic glomerulonephritis and ulcerative-necrotic vasculitis in patients with Sjögren's disease]. Ter Arkh (1987) 0.75

[Objective assessment of serological methods in the diagnosis of systemic lupus erythematosus]. Ter Arkh (1987) 0.75

[Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes]. Biull Eksp Biol Med (1988) 0.75

[Clinical value of determining the anti-DNA antibodies with different avidities in systemic lupus erythematosus]. Ter Arkh (1987) 0.75

[Interleukin 1 and its role in human pathology]. Ter Arkh (1987) 0.75

[Antimitochrondrial antibodies in chronic liver diseases]. Sov Med (1976) 0.75

[Differential diagnosis of Mikulicz's disease and Sjögren's disease]. Stomatologiia (Mosk) (1988) 0.75

[Cryptorchism and its surgical treatment]. Khirurgiia (Mosk) (1989) 0.75

[Antibodies reacting with the antigens of the human immunodeficiency virus in systemic lupus erythematosus]. Ter Arkh (1987) 0.75

[IgG4-related disease: patient group characterization and rituximab therapy]. Ter Arkh (2013) 0.75

[Ketamine anesthesia in operations on the organs of the abdominal cavity]. Voen Med Zh (1976) 0.75

[Antinuclear antibodies in Sjögren's disease and syndrome]. Ter Arkh (1986) 0.75

[Ventilation with atmospheric air during ketamine anesthesia]. Voen Med Zh (1978) 0.75

[Role of the immunofluorescence technic in diagnosis of chronic liver diseases]. Ter Arkh (1978) 0.75

[Circulating immune complexes and cellular cytotoxic reactions in Sjögren's syndrome]. Ter Arkh (1988) 0.75

[Diagnosis of rejection crisis of testicular allotransplant]. Klin Khir (1975) 0.75

[In vitro lymphocyte-fibroblast relationship in Sjögren's syndrome]. Ter Arkh (1979) 0.75

[External respiratory function in acute pneumonias in young patients]. Voen Med Zh (1974) 0.75

[Extracorporeal therapy (hemosorption, plasmapheresis) in the combined treatment of severe forms of Sjögren's disease]. Vutr Boles (1988) 0.75

[Opioid peptides as regulators of the immune system]. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR (1987) 0.75

[Autoimmune component in chronic active hepatitis and its connection with isolation of the hepatitis B surface antigen]. Ter Arkh (1977) 0.75

[Clinical significance of antibodies to the smooth musculature in chronic active hepatitis]. Klin Med (Mosk) (1980) 0.75